PL3448364T3 - Celowanie we wrodzony układ immunologiczny dla wywołania długotrwałej tolerancji i wyeliminowania akumulacji makrofagów w miażdżycy naczyń - Google Patents
Celowanie we wrodzony układ immunologiczny dla wywołania długotrwałej tolerancji i wyeliminowania akumulacji makrofagów w miażdżycy naczyńInfo
- Publication number
- PL3448364T3 PL3448364T3 PL17790646.8T PL17790646T PL3448364T3 PL 3448364 T3 PL3448364 T3 PL 3448364T3 PL 17790646 T PL17790646 T PL 17790646T PL 3448364 T3 PL3448364 T3 PL 3448364T3
- Authority
- PL
- Poland
- Prior art keywords
- atherosclerosis
- resolve
- targeting
- immune system
- innate immune
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
- A61K51/1224—Lipoprotein vesicles, e.g. HDL and LDL proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662329676P | 2016-04-29 | 2016-04-29 | |
| PCT/US2017/030444 WO2017190145A1 (en) | 2016-04-29 | 2017-05-01 | Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3448364T3 true PL3448364T3 (pl) | 2022-08-16 |
Family
ID=60161161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17790646.8T PL3448364T3 (pl) | 2016-04-29 | 2017-05-01 | Celowanie we wrodzony układ immunologiczny dla wywołania długotrwałej tolerancji i wyeliminowania akumulacji makrofagów w miażdżycy naczyń |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190290593A1 (pl) |
| EP (2) | EP3448364B1 (pl) |
| JP (2) | JP7262100B2 (pl) |
| CN (2) | CN116077439A (pl) |
| AU (2) | AU2017257189B2 (pl) |
| CA (1) | CA3021645A1 (pl) |
| DK (1) | DK3448364T3 (pl) |
| ES (1) | ES2913073T3 (pl) |
| PL (1) | PL3448364T3 (pl) |
| PT (1) | PT3448364T (pl) |
| WO (1) | WO2017190145A1 (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112218619A (zh) * | 2017-11-20 | 2021-01-12 | 西奈山伊坎医学院 | 通过治疗性纳米生物制剂组合物抑制驯化免疫 |
| JP2022541582A (ja) * | 2019-07-19 | 2022-09-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 自己免疫障害を処置するための組成物および方法 |
| CA3162617A1 (en) * | 2019-11-22 | 2021-05-27 | The Research Foundation For The State University Of New York | Compositions and methods for use in type 1 diabetes |
| CN111494320A (zh) * | 2020-04-24 | 2020-08-07 | 上海交通大学医学院附属仁济医院 | 一种载糖皮质激素的纳米载体及其制备和应用 |
| WO2022198101A1 (en) * | 2021-03-19 | 2022-09-22 | Trained Therapeutix Discovery, Inc. | Compounds for regulating trained immunity, and their methods of use |
| CN114788835B (zh) * | 2022-04-07 | 2024-01-23 | 中山大学附属第三医院 | Foxp3阳性巨噬细胞在制备治疗急性脑梗死药物中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5540931A (en) * | 1989-03-03 | 1996-07-30 | Charles W. Hewitt | Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| CN1046944C (zh) | 1993-12-17 | 1999-12-01 | 山道士有限公司 | 雷怕霉素类衍生物 |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| CZ292233B6 (cs) | 1995-06-09 | 2003-08-13 | Novartis Ag | Deriváty rapamycinu a jejich použití jako léčiv |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| WO2001085208A2 (en) | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
| CA2319928A1 (en) | 2000-09-18 | 2002-03-18 | Vasogen Ireland Limited | Apoptosis-mimicking synthetic entities and use thereof in medical treatments |
| GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
| WO2004084940A1 (en) | 2003-03-26 | 2004-10-07 | Cytos Biotechnology Ag | Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use |
| DK1704585T3 (en) | 2003-12-19 | 2017-05-22 | Univ North Carolina Chapel Hill | Methods for preparing isolated micro- and nanostructures using soft lithography or printing lithography |
| AU2005326322B2 (en) | 2004-07-01 | 2009-02-05 | Yale University | Targeted and high density drug loaded polymeric materials |
| AU2008236566A1 (en) | 2007-04-09 | 2008-10-16 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
| MX2010003642A (es) | 2007-10-12 | 2010-08-09 | Massachusetts Inst Technology | Nanotecnologia de vacuna. |
| WO2009106999A2 (en) | 2008-02-28 | 2009-09-03 | Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts | Hollow nanoparticles and uses thereof |
| WO2010047839A1 (en) | 2008-10-25 | 2010-04-29 | Aura Biosciences | Modified plant virus particles and uses therefor |
| US10525152B2 (en) * | 2009-10-09 | 2020-01-07 | Signablok, Inc. | Methods and compositions for targeted imaging |
| KR101253399B1 (ko) * | 2010-10-26 | 2013-04-11 | 영남대학교 산학협력단 | 아포지단백질 ａ－ｉ 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형 |
| US20150182461A1 (en) * | 2012-06-19 | 2015-07-02 | Massachussets Institute Of Technology | Mass Production and Size Control of Nanoparticles Through Controlled Microvortices |
| EP2703384A1 (en) | 2012-08-27 | 2014-03-05 | Ludwig-Maximilians-Universität München | Inhibitors of CD40-TRAF6 interaction |
| WO2016019333A1 (en) * | 2014-07-31 | 2016-02-04 | Kinemed, Inc. | The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties |
| CA3008837A1 (en) * | 2015-12-18 | 2017-06-22 | Northwestern University | Nitric oxide releasing high density lipoprotein-like nanoparticles (no hdl nps) |
-
2017
- 2017-05-01 EP EP17790646.8A patent/EP3448364B1/en active Active
- 2017-05-01 CN CN202310107087.1A patent/CN116077439A/zh active Pending
- 2017-05-01 AU AU2017257189A patent/AU2017257189B2/en active Active
- 2017-05-01 DK DK17790646.8T patent/DK3448364T3/da active
- 2017-05-01 EP EP22155443.9A patent/EP4014967A1/en active Pending
- 2017-05-01 US US16/097,013 patent/US20190290593A1/en not_active Abandoned
- 2017-05-01 ES ES17790646T patent/ES2913073T3/es active Active
- 2017-05-01 PL PL17790646.8T patent/PL3448364T3/pl unknown
- 2017-05-01 PT PT177906468T patent/PT3448364T/pt unknown
- 2017-05-01 WO PCT/US2017/030444 patent/WO2017190145A1/en active Application Filing
- 2017-05-01 CN CN201780041257.3A patent/CN109640959B/zh active Active
- 2017-05-01 JP JP2018556339A patent/JP7262100B2/ja active Active
- 2017-05-01 CA CA3021645A patent/CA3021645A1/en active Pending
-
2022
- 2022-06-30 AU AU2022204675A patent/AU2022204675A1/en active Pending
-
2023
- 2023-03-14 US US18/121,527 patent/US20230218537A1/en active Pending
- 2023-04-04 JP JP2023060872A patent/JP2023085437A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230218537A1 (en) | 2023-07-13 |
| CN116077439A (zh) | 2023-05-09 |
| US20190290593A1 (en) | 2019-09-26 |
| AU2017257189A1 (en) | 2018-11-15 |
| PT3448364T (pt) | 2022-05-04 |
| EP3448364B1 (en) | 2022-02-09 |
| EP3448364A1 (en) | 2019-03-06 |
| CA3021645A1 (en) | 2017-11-02 |
| WO2017190145A1 (en) | 2017-11-02 |
| JP2019515926A (ja) | 2019-06-13 |
| AU2017257189B2 (en) | 2022-03-31 |
| EP4014967A1 (en) | 2022-06-22 |
| DK3448364T3 (da) | 2022-05-02 |
| CN109640959A (zh) | 2019-04-16 |
| AU2022204675A1 (en) | 2022-09-15 |
| CN109640959B (zh) | 2023-03-17 |
| EP3448364A4 (en) | 2019-12-25 |
| JP7262100B2 (ja) | 2023-04-21 |
| ES2913073T3 (es) | 2022-05-31 |
| JP2023085437A (ja) | 2023-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3448364T3 (pl) | Celowanie we wrodzony układ immunologiczny dla wywołania długotrwałej tolerancji i wyeliminowania akumulacji makrofagów w miażdżycy naczyń | |
| IL257571A (en) | A system for creating a spray with a condenser | |
| GB2550066B8 (en) | Online collaboration systems and methods | |
| HK1214912A2 (zh) | 可多角度"彎折"鏡腿的眼鏡 | |
| IL259202A (en) | Modified immune cells and their use | |
| GB201601828D0 (en) | Noise compensation in speaker-adaptive system | |
| ZA201808059B (en) | Improvements in or relating to connecting devices | |
| IL258667A (en) | Improvements in/and related to missile homing | |
| PL3047159T3 (pl) | Łącznik do profili jak również zespolenie profili | |
| GB2595602B (en) | Improvements in and relating to heating and cooling systems | |
| ZA201701782B (en) | Rail member and rail system | |
| PL3274637T3 (pl) | Kocioł i drzwi do tego kotła | |
| EP3174984A4 (en) | Antagonistic ctla-4 aptamers and applications thereof in enhancing immune activity | |
| GB2563535B (en) | Improvements in and relating to video multiviewer systems | |
| GB2552573B (en) | Interactive greeting card with infrared sensor | |
| HK1225820A1 (zh) | 計算機化的家具組件和相關的多媒體系統 | |
| GB201515226D0 (en) | Improvements in or relating to heating and cooling systems | |
| GB2545227B (en) | Improvements in and relating to remote sensing | |
| GB201513570D0 (en) | Improvements in and relating to wall coverings | |
| GB2545341B (en) | Improvements in and relating to remote sensing | |
| GB201620632D0 (en) | Improvements in and relating to remote sensing | |
| GB201620626D0 (en) | Improvements in and relating to remote sensing | |
| GB201509183D0 (en) | Improvements in and relating to munitions systems | |
| GB201604852D0 (en) | Connector assembly and retaining bush | |
| GB201513116D0 (en) | Improvements in and relating to plastics |